- $86.51m
- $78.81m
- $1.88m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 45.99 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -219.52% | ||
| Return on Equity | -1487.09% | ||
| Operating Margin | -3245.14% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.22 | 2.2 | 0.96 | 1.5 | 1.88 | 1.02 | 3.83 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Oncocyte Corporation is a precision diagnostics company. The Company is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. The Company’s products include DetermaIO, VitaGraft, DetermaCNI and GraftAssure. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaIO measures the expression level of 27 selected genes, which are interpreted through the use of a proprietary algorithm (patent pending) which computes a quantitative score (IO Score) that incorporates information from the immune inflammatory infiltrates within and around the tumor. Its pipeline test, DetermaCNI, is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. VitaGraft is a blood-based solid organ transplantation monitoring test. GraftAssure is a research use only blood-based solid organ transplantation monitoring test.
Directors
- Cavan Redmond NEC (60)
- Ronald Andrews PRE (60)
- Mitchell Levine CFO
- Gisela Paulsen COO (55)
- Li Yu CAO
- Douglas Ross OTH
- Padma Sundar OTH
- Andrew Arno IND (61)
- Jennifer Carter IND (57)
- Melinda Griffith IND (66)
- Alfred Kingsley IND (78)
- Andrew Last IND (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 30th, 2009
- Public Since
- December 30th, 2015
- No. of Shareholders
- 182
- No. of Employees
- 46
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 28,599,285
- Address
- 15 CUSHING, IRVINE, 92618
- Web
- https://oncocyte.com/
- Phone
- +1 9494097600
- Auditors
- Marcum LLP
Upcoming Events for OCX
Q2 2025 OncoCyte Corp Earnings Release
OncoCyte Corp Annual Shareholders Meeting
Similar to OCX
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Oncocyte share price?
As of Today at 22:27 UTC, shares in Oncocyte are trading at $3.03. This share price information is delayed by 15 minutes.
How has the Oncocyte share price performed this year?
Shares in Oncocyte last closed at $3.03 and the price had moved by +8.84% over the past 365 days. In terms of relative price strength the Oncocyte share price has underperformed the S&P500 Index by -1.86% over the past year.
What are the analyst and broker recommendations for Oncocyte?
The overall consensus recommendation for Oncocyte is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Oncocyte dividend yield?
Oncocyte does not currently pay a dividend.
Does Oncocyte pay a dividend?
Oncocyte does not currently pay a dividend.
When does Oncocyte next pay dividends?
Oncocyte does not currently pay a dividend.
How do I buy Oncocyte shares?
To buy shares in Oncocyte you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Oncocyte?
As of the previous close price of $3.03, shares in Oncocyte had a market capitalisation of $86.51m.
Where are Oncocyte shares listed?
Here are the trading details for Oncocyte:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: OCX
What kind of share is Oncocyte?
Based on an overall assessment of its quality, value and momentum Oncocyte is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Oncocyte share price forecast for 2025?
The analyst consensus target price for shares in Oncocyte is $4.50. That is 48.76% above the last closing price of $3.03.
Analysts covering Oncocyte currently have a consensus Earnings Per Share (EPS) forecast of -$0.90 for the next financial year.
Find out moreWhat is the trend in the Oncocyte share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oncocyte. Over the past six months, its share price has outperformed the S&P500 Index by +1.29%.
As of the last closing price of $3.03, shares in Oncocyte were trading +6.28% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Oncocyte PE Ratio?
The Oncocyte PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Oncocyte?
Oncocyte's management team is headed by:
- Cavan Redmond - NEC
- Ronald Andrews - PRE
- Mitchell Levine - CFO
- Gisela Paulsen - COO
- Li Yu - CAO
- Douglas Ross - OTH
- Padma Sundar - OTH
- Andrew Arno - IND
- Jennifer Carter - IND
- Melinda Griffith - IND
- Alfred Kingsley - IND
- Andrew Last - IND